Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool?
Overactive bladder syndrome (OAB) is a highly prevalent urinary dysfunction, with considerable economic and human costs. Clinical diagnosis of OAB is still based on subjective symptoms. A new accurate, objective and noninvasive test to diagnose OAB and assess therapeutic outcome is lacking. Recent s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2011/382431 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849397443317202944 |
|---|---|
| author | Tiago Antunes-Lopes Sérgio Carvalho-Barros Célia-Duarte Cruz Francisco Cruz Carlos Martins-Silva |
| author_facet | Tiago Antunes-Lopes Sérgio Carvalho-Barros Célia-Duarte Cruz Francisco Cruz Carlos Martins-Silva |
| author_sort | Tiago Antunes-Lopes |
| collection | DOAJ |
| description | Overactive bladder syndrome (OAB) is a highly prevalent urinary
dysfunction, with considerable economic and human costs. Clinical diagnosis of OAB is still based on subjective symptoms. A new
accurate, objective and noninvasive test to diagnose OAB and assess therapeutic outcome is lacking. Recent studies in lower
urinary tract (LUT) dysfunctions, particularly in OAB patients, indicate that urinary proteins (neurotrophins, prostaglandins, and
cytokines), serum C reactive protein, and detrusor wall thickness are altered, and such changes could be used as biomarkers of the
disease. Nowadays, increasing emphasis has been given to the role of urinary neurotrophins, namely nerve growth factor (NGF) and
brain derived neurotrophic factor (BDNF), as key players in some urinary dysfunctions. Although recently considered to be a bladder
dysfunction biomarker, urinary NGF presents low sensitivity and specificity. Preliminary results suggest that BDNF may serve as a
more efficient biomarker. Even though we have to wait for future studies to confirm the potential role of NGF and BDNF as OAB
biomarkers, it is already clear that neurotrophins will contribute to elucidate the physiopathological basis of OAB. Herein are
reviewed the latest advances in this new and exciting field, the detection and clinical application of emerging OAB biomarkers. |
| format | Article |
| id | doaj-art-aea8734ceeb943d080925b95ed6f6684 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-aea8734ceeb943d080925b95ed6f66842025-08-20T03:38:59ZengWileyAdvances in Urology1687-63691687-63772011-01-01201110.1155/2011/382431382431Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool?Tiago Antunes-Lopes0Sérgio Carvalho-Barros1Célia-Duarte Cruz2Francisco Cruz3Carlos Martins-Silva4Department of Urology, Hospital de S. João, 4200-319 Porto, PortugalInstituto de Biologia e Molecular e Celular (IBMC), University of Porto, 4150-180 Porto, PortugalInstituto de Biologia e Molecular e Celular (IBMC), University of Porto, 4150-180 Porto, PortugalDepartment of Urology, Hospital de S. João, 4200-319 Porto, PortugalDepartment of Urology, Hospital de S. João, 4200-319 Porto, PortugalOveractive bladder syndrome (OAB) is a highly prevalent urinary dysfunction, with considerable economic and human costs. Clinical diagnosis of OAB is still based on subjective symptoms. A new accurate, objective and noninvasive test to diagnose OAB and assess therapeutic outcome is lacking. Recent studies in lower urinary tract (LUT) dysfunctions, particularly in OAB patients, indicate that urinary proteins (neurotrophins, prostaglandins, and cytokines), serum C reactive protein, and detrusor wall thickness are altered, and such changes could be used as biomarkers of the disease. Nowadays, increasing emphasis has been given to the role of urinary neurotrophins, namely nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF), as key players in some urinary dysfunctions. Although recently considered to be a bladder dysfunction biomarker, urinary NGF presents low sensitivity and specificity. Preliminary results suggest that BDNF may serve as a more efficient biomarker. Even though we have to wait for future studies to confirm the potential role of NGF and BDNF as OAB biomarkers, it is already clear that neurotrophins will contribute to elucidate the physiopathological basis of OAB. Herein are reviewed the latest advances in this new and exciting field, the detection and clinical application of emerging OAB biomarkers.http://dx.doi.org/10.1155/2011/382431 |
| spellingShingle | Tiago Antunes-Lopes Sérgio Carvalho-Barros Célia-Duarte Cruz Francisco Cruz Carlos Martins-Silva Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool? Advances in Urology |
| title | Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool? |
| title_full | Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool? |
| title_fullStr | Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool? |
| title_full_unstemmed | Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool? |
| title_short | Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool? |
| title_sort | biomarkers in overactive bladder a new objective and noninvasive tool |
| url | http://dx.doi.org/10.1155/2011/382431 |
| work_keys_str_mv | AT tiagoantuneslopes biomarkersinoveractivebladderanewobjectiveandnoninvasivetool AT sergiocarvalhobarros biomarkersinoveractivebladderanewobjectiveandnoninvasivetool AT celiaduartecruz biomarkersinoveractivebladderanewobjectiveandnoninvasivetool AT franciscocruz biomarkersinoveractivebladderanewobjectiveandnoninvasivetool AT carlosmartinssilva biomarkersinoveractivebladderanewobjectiveandnoninvasivetool |